N
Nadia Amellal
Researcher at Merck KGaA
Publications - 48
Citations - 10176
Nadia Amellal is an academic researcher from Merck KGaA. The author has contributed to research in topics: Bevacizumab & Cetuximab. The author has an hindex of 15, co-authored 39 publications receiving 9276 citations.
Papers
More filters
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken,Ricard Mesia,Fernando Rivera,Eva Remenar,Andrzej Kawecki,Sylvie Rottey,Jozsef Erfan,Dmytro Zabolotnyy,Heinz Roland Kienzer,Didier Cupissol,Frederic Peyrade,Marco Benasso,Ihor Vynnychenko,Dominique De Raucourt,Carsten Bokemeyer,Armin Schueler,Nadia Amellal,Ricardo Hitt +17 more
TL;DR: Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracils) significantly prolonged the median overall survival and improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
Jan B. Vermorken,Jose Manuel Trigo,Ricardo Hitt,Piotr Koralewski,Eduardo Díaz-Rubio,Frederic Rolland,Rainald Knecht,Nadia Amellal,Armin Schueler,José Baselga +9 more
TL;DR: Single-agent cetuximab was active and generally well tolerated in the treatment of recurrent and/or metastatic SCCHN that progressed on platinum therapy and response was comparable to that seen with cetUXimab plus platinum combination regimens in the same setting.
Journal ArticleDOI
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Jose Baselga,Jose Manuel Trigo,Jean Bourhis,Jacques Tortochaux,Hernán Cortés-Funes,Ricardo Hitt,Pere Gascón,Nadia Amellal,Andreas Harstrick,André Eckardt +9 more
TL;DR: The combination of cetuximab and platinum chemotherapy is an active and well-tolerated approach to the treatment of this poor-prognosis patient population with platinum-refractory recurrent or metastatic SCCHN for whom there are no recommended standard therapeutic options.
Journal ArticleDOI
Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab
Desmond Curran,Jordi Giralt,Paul M. Harari,K. Kian Ang,Roger B. Cohen,Merrill S. Kies,Jacek Jassem,José Baselga,Eric K. Rowinsky,Nadia Amellal,Sylvie Comte,James A. Bonner +11 more
TL;DR: The addition of cetuximab to radiotherapy significantly improved locoregional control and increased overall survival without adversely affecting QoL.